Artificial intelligence is working its way into all aspects of pharmaceutical companies’ operations. While much attention has been given to the role these systems can play in drug discovery, IQVIA sees a significant opportunity to use them to transform the area of regulatory compliance. We spoke to Ronan Brown, senior vice president and head of IQVIA Integrated Global Compliance, about the role AI system can play in improving flagging returns on investment in R&D by allowing regulatory departments to operate more efficiently, breakdown data silos within pharmaceutical companies that hamper performance, and allow companies to focus less on rote work and more on regulatory strategies.
